Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clinical trials, major issues remain.
The challengesofimplementingclinicaltrialsat a time of limited researchfundingareconsiderable, andmanyare never completedbecausethey don't reachenrolmentrequirements.